A Phase 1, Randomized, Placebo controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ACP-014 in Healthy Adult Subjects (ACP-014 -Phase 1)
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs TransCon PTH (Primary)
- Indications Hypoparathyroidism
- Focus Adverse reactions; First in man
- Sponsors Ascendis Pharma Bone Diseases
- 06 Oct 2017 New trial record
- 26 Sep 2017 According to an Ascendis Pharma media release, first patient has been dosed in this trial.
- 18 Aug 2017 According to an Ascendis Pharma A/S media release, the company submitted regulatory filings in Australia to enable initiation of this trial.